Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978045 | 0.94 | CNR1 (0.48) | CNR1CNR2PPARDALDH1A1 | |
| SCHEMBL9978217 | 0.91 | CNR1 (0.50) | CNR1CNR2PPARDALDH1A1 | |
| SCHEMBL9978177 | 0.90 | PPARD (0.52) | CNR1CNR2PPARDSMN1; SMN2 | |
| SCHEMBL9978214 | 0.89 | CNR2 (0.48) | CNR1CNR2PPARDNPC1RAB9A | |
| SCHEMBL9978036 | 0.88 | MTNR1A (0.47) | CNR1CNR2PPARDMTNR1AMTNR1B | |
| SCHEMBL9978063 | 0.88 | CNR2 (0.48) | CNR1CNR2PPARDALDH1A1 | |
| SCHEMBL9978006 | 0.87 | CNR1 (0.48) | CNR1CNR2PPARD | |
| SCHEMBL9978222 | 0.87 | CNR2 (0.50) | CNR1CNR2PPARD | |
| SCHEMBL9978004 | 0.87 | CNR1 (0.48) | CNR1CNR2PPARDNPC1RAB9A | |
| SCHEMBL9978008 | 0.87 | CNR1 (0.48) | CNR1CNR2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925251-B2 | Treatments for Mycobacterium tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925251-B2 | Treatments for Mycobacterium tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-27 | — | — | US | disclosed |
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | disclosed |
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | disclosed |
| WO-2013059622-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012079164-A1 | ACTIVATORS OF CYLINDRICAL PROTEASES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | CLPP, LONP1, CLPX | CNR1 4284/4885CNR2 4428/4885PPARD 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.